- Home
- LLYVK vs ROIV Comparison
LLYVK vs ROIV Comparison
Compare LLYVK & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVK
- ROIV
- Stock Information
- Founded
- LLYVK 1991
- ROIV 2014
- Country
- LLYVK United States
- ROIV United Kingdom
- Employees
- LLYVK N/A
- ROIV N/A
- Industry
- LLYVK Broadcasting
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- LLYVK Industrials
- ROIV Health Care
- Exchange
- LLYVK Nasdaq
- ROIV Nasdaq
- Market Cap
- LLYVK 8.6B
- ROIV 8.6B
- IPO Year
- LLYVK N/A
- ROIV N/A
- Fundamental
- Price
- LLYVK $90.44
- ROIV $19.58
- Analyst Decision
- LLYVK
- ROIV Strong Buy
- Analyst Count
- LLYVK 0
- ROIV 8
- Target Price
- LLYVK N/A
- ROIV $21.06
- AVG Volume (30 Days)
- LLYVK 231.2K
- ROIV 7.6M
- Earning Date
- LLYVK 01-01-0001
- ROIV 11-10-2025
- Dividend Yield
- LLYVK N/A
- ROIV N/A
- EPS Growth
- LLYVK N/A
- ROIV N/A
- EPS
- LLYVK N/A
- ROIV N/A
- Revenue
- LLYVK N/A
- ROIV $23,233,000.00
- Revenue This Year
- LLYVK N/A
- ROIV N/A
- Revenue Next Year
- LLYVK $11.37
- ROIV $320.50
- P/E Ratio
- LLYVK N/A
- ROIV N/A
- Revenue Growth
- LLYVK N/A
- ROIV N/A
- 52 Week Low
- LLYVK $57.62
- ROIV $8.73
- 52 Week High
- LLYVK $102.62
- ROIV $18.96
- Technical
- Relative Strength Index (RSI)
- LLYVK 42.91
- ROIV 81.18
- Support Level
- LLYVK $89.92
- ROIV $17.89
- Resistance Level
- LLYVK $94.11
- ROIV $18.96
- Average True Range (ATR)
- LLYVK 1.77
- ROIV 0.50
- MACD
- LLYVK 0.03
- ROIV 0.06
- Stochastic Oscillator
- LLYVK 35.09
- ROIV 95.45
About LLYVK Liberty Media Corporation
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.